Endocrine Abstracts

Androgen ablation therapy remains the most common treatment for patients with advanced prostate cancer (PCa). However, most patients relapse and develop a castration-resistant PCa. The emergence of androgen receptor (AR) variants, such as constitutively active ARs, has been involved in this failure to androgen deprivation. Nevertheless, the tumour microenvironment is another necessary feature driving PCa progression. Cancer associated fibroblasts (CAFs) are one of the speciali...